TP53 and breast carcinoma: McCuaig et al. estimated that 5–8% of women with breast cancer diagnosed under age 30 years and no pathogenic variant in BRCA1 or BRCA2 will have a pathogenic variant in TP53, and a smaller proportion of women with breast cancer diagnosed aged 30–39 years [12].